Síguenos en Twitter     Síguenos en Facebook     Síguenos en YouTube     Siguenos en Linkedin     Correo Salutsantjoan     Gmail     Dropbox     Instagram     Google Drive     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon

SOBRE EL AUTOR **

My photo
FACP. Colegio de médicos de Tarragona Nº 4305520 / fgcapriles@gmail.com

WORLD EMERGENCY MEDICINE SOCIETIES & RELATED

Search

Content:

Monday, January 9, 2023

Diltiazem vs Metoprolol in AF+HFrEF

SGEM#388 - By admin - January 07, 2023
CLINICAL QUESTION: IN PATIENTS WITH HFrEF PRESENTING TO THE ED IN AF WITH RVR, ARE THERE SIGNIFICANT DIFFERENCES IN ADVERSE OUTCOMES FOR PATIENTS TREATED WITH IV DILTIAZEM VS IV METOPROLOL?
KEY RESULT: NO STATISTICAL DIFFERENCE IN ADVERSE EFFECTS DUE TO THE INTERVENTIONS
  • No statistical difference in any of the components of the composite outcome except for worsening CHF symptoms (33% vs. 15%, P = 0.019).
  • Worsening CHF was driven by increased oxygen requirement within four hours
SGEM BOTTOM LINE: THERE IS INSUFFICIENT EVIDENCE TO SUGGEST A DIFFERENCE IN TOTAL ADVERSE OUTCOMES FOR PATIENTS PRESENTING TO THE ED IN ATRIAL FIBRILLATION WITH RAPID VENTRICULAR RESPONSE TREATED WITH IV DILTIAZEM VS METOPROLOL.